Zidovudine (AZT) for treatment of patients infected with human immunodeficiency virus type 1. An evaluation of effectiveness in clinical practice.
Colson ER, Horwitz RI, Bia FJ, Viscoli CM. Zidovudine (AZT) for treatment of patients infected with human immunodeficiency virus type 1. An evaluation of effectiveness in clinical practice. JAMA Internal Medicine 1991, 151: 709-13. PMID: 2012453, DOI: 10.1001/archinte.151.4.709.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultCohort StudiesConnecticutEvaluation Studies as TopicFemaleFollow-Up StudiesHIV-1HumansMaleTime FactorsZidovudineConceptsZidovudine therapyDosage reductionAdverse outcomesHuman immunodeficiency virus type 1 (HIV-1) infectionClinical practiceHuman immunodeficiency virus type 1Virus type 1 infectionImmunodeficiency virus type 1Observational cohort studyHuman immunodeficiency virusTreatment of patientsType 1 infectionVirus type 1Zidovudine dosageCohort studyMost patientsImmunodeficiency virusBaseline cytopeniasTreatment outcomesPatterns of usePatientsTherapyType 1Dosage changesMonths